Resistance to trastuzumab in breast cancer PR Pohlmann, IA Mayer, R Mernaugh Clinical cancer research 15 (24), 7479-7491, 2009 | 620 | 2009 |
Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. ISPY Investigators N Engl J Med 375 (1), 23-34, 2016 | 598* | 2016 |
Adaptive Randomization of Neratinib in Early Breast Cancer. ISPY Investigators, ... N Engl J Med 375 (1), 11-22, 2016 | 373* | 2016 |
TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2–positive breast cancer and brain metastases RA Freedman, RS Gelman, CK Anders, ME Melisko, HA Parsons, ... Journal of Clinical Oncology 37 (13), 1081-1089, 2019 | 330 | 2019 |
Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial S Adams, JR Diamond, E Hamilton, PR Pohlmann, SM Tolaney, ... JAMA oncology 5 (3), 334-342, 2019 | 276 | 2019 |
Kinome-wide RNA interference screen reveals a role for PDK1 in acquired resistance to CDK4/6 inhibition in ER-positive breast cancer VM Jansen, NE Bhola, JA Bauer, L Formisano, KM Lee, KE Hutchinson, ... Cancer research 77 (9), 2488-2499, 2017 | 226 | 2017 |
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma H Hatakeyama, H Cheng, P Wirth, A Counsell, SR Marcrom, CB Wood, ... PloS one 5 (9), e12702, 2010 | 178 | 2010 |
Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). S Adams, JR Diamond, EP Hamilton, PR Pohlmann, SM Tolaney, ... Journal of clinical oncology 34 (15_suppl), 1009-1009, 2016 | 167 | 2016 |
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies DM Wolf, C Yau, J Wulfkuhle, L Brown-Swigart, RI Gallagher, PRE Lee, ... Cancer Cell 40 (6), 609-623. e6, 2022 | 154 | 2022 |
Accuracy of frozen-section analysis in the diagnosis of ovarian tumors: a systematic quantitative review LR Medeiros, DD Rosa, MI Edelweiss, AT Stein, MC Bozzetti, ... International Journal of Gynecologic Cancer 15 (2), 2005 | 152 | 2005 |
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study F Lynce, A Barac, X Geng, C Dang, AF Yu, KL Smith, C Gallagher, ... Breast cancer research and treatment 175, 595-603, 2019 | 130 | 2019 |
Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): a randomized clinical trial SM Tolaney, N Tayob, C Dang, DA Yardley, SJ Isakoff, V Valero, ... Journal of Clinical Oncology 39 (21), 2375-2385, 2021 | 118 | 2021 |
CXCL8 secretion by dendritic cells predicts contact allergens from irritants MJ Toebak, PR Pohlmann, SC Sampat-Sardjoepersad, ... Toxicology in Vitro 20 (1), 117-124, 2006 | 118 | 2006 |
Adjuvant platinum‐based chemotherapy for early stage cervical cancer DD Rosa, LRF Medeiros, MI Edelweiss, PR Pohlmann, AT Stein Cochrane Database of Systematic Reviews, 2012 | 113 | 2012 |
Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix P Pohlmann, LP DiLeone, AI Cancella, APF Caldas, L Dal Lago, ... American journal of clinical oncology 25 (5), 496-501, 2002 | 107 | 2002 |
Optical metabolic imaging of treatment response in human head and neck squamous cell carcinoma AT Shah, M Demory Beckler, AJ Walsh, WP Jones, PR Pohlmann, ... PloS one 9 (3), e90746, 2014 | 106 | 2014 |
Adjuvant platinum‐based chemotherapy for early stage cervical cancer FS Falcetta, LRF Medeiros, MI Edelweiss, PR Pohlmann, AT Stein, ... Cochrane Database of Systematic Reviews, 2016 | 96 | 2016 |
A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies G Schwartsmann, LP DiLeone, M Horowitz, D Schunemann, A Cancella, ... Investigational new drugs 24, 403-412, 2006 | 96 | 2006 |
A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients MJ Pishvaian, EM Blais, RJ Bender, S Rao, SM Boca, V Chung, ... JAMIA open 2 (4), 505-515, 2019 | 63 | 2019 |
Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer S Adams, J Diamond, E Hamilton, P Pohlmann, S Tolaney, L Molinero, ... Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer …, 2015 | 57 | 2015 |